Clinical Trial

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Protocol Amendment History 1 change
notable Trial sites expanded: 9 -> 13 locations 2026-05-29
Trial Details
NCT Number NCT07020819
Lead Sponsor Annexon, Inc.
Conditions Guillain-Barre Syndrome
Enrollment 30 participants
Start Date 2025-09-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-28